Full-Dose Heparin Benefit in Certain COVID-19 Patients Confirmed
A therapeutic dose of heparin was associated with increased probability of survival for non-critically ill COVID-19 patients versus usual-care thromboprophylaxis, but not for the most severe patient population, peer-reviewed results from the REMAP-CAP, ACTIV-4a, and ATTACC multi-platform trial showed. In the non-critically ill cohort, therapeutic dose anticoagulation with heparin was superior to usual care prophylaxis, […]